Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to United Therapeutics Corporation (NASDAQ: UTHR) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret key disclosures. United Therapeutics is a biotechnology and pharmaceutical company whose common stock trades on the Nasdaq Global Select Market, as noted in its Form 8-K reports. The company develops therapies for pulmonary arterial hypertension and related lung diseases and pursues technologies to expand the availability of transplantable organs as part of its public benefit corporation mandate.
In these SEC filings, investors can review current reports on Form 8-K that describe material events such as quarterly earnings releases, clinical milestones, share repurchase arrangements, and shareholder meeting outcomes. For example, United Therapeutics has filed 8-Ks to furnish press releases on quarterly financial results, to report positive TETON-2 clinical data for nebulized Tyvaso in idiopathic pulmonary fibrosis, and to disclose accelerated share repurchase agreements under a board-authorized share repurchase program.
Filings also document corporate governance and compensation matters, including amendments and restatements of the company’s stock incentive plan, vote results from the annual meeting of shareholders, and the listing of common stock on the Nasdaq Global Select Market under the symbol UTHR. These documents provide insight into equity compensation structures, director elections, advisory votes on executive pay, and auditor ratification.
Through this page, you can quickly locate United Therapeutics’ 8-Ks and, where available, other forms such as 10-K annual reports, 10-Q quarterly reports, and Forms 3, 4, and 5 related to insider ownership and transactions. AI-powered summaries highlight the main points of lengthy filings, explain complex sections in simpler language, and draw attention to items that often matter to investors, such as revenue drivers, capital return actions, and significant clinical or regulatory updates. Real-time updates from EDGAR ensure that new UTHR filings appear promptly, helping users monitor the company’s regulatory and disclosure record in one place.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a pre-planned transaction. On April 9, 2026, he exercised options for 10,000 shares of Common Stock at an exercise price of $135.42 per share.
On the same date, he sold a total of 10,000 shares of Common Stock in multiple open-market trades at prices reported between about $574.18 and $582.30. These transactions were made under a Rule 10b5-1 trading plan entered into on October 31, 2025, indicating they were pre-scheduled.
Following the transactions, Edgemond directly owned 18,876 shares of UNITED THERAPEUTICS Common Stock, maintaining a meaningful equity stake while monetizing the shares received from the option exercise.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in open-market transactions. The sales occurred at prices around the mid-$570s to low-$580s per share, with reported weighted average prices including $575.04 and $580.84.
The exercise and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026. Following these transactions, Rothblatt directly holds 40,513 shares of common stock and 74,000 stock options, with additional indirect holdings through a spouse and multiple family trusts.
United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options and sold shares in a pre-planned transaction. On April 8, 2026, she exercised options for 9,500 shares of common stock at an exercise price of $146.03 per share and received 9,500 shares.
That same day, she sold 9,500 shares of common stock in multiple open-market trades at prices generally ranging from about $565 to $586 per share, leaving 40,513 shares held directly. Additional common shares are held indirectly through her spouse and various family trusts as described in the filing. All option exercises and related sales occurred under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold the resulting shares under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. She exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
On the same date, she sold 9,500 shares of common stock in multiple open-market trades, with reported prices including $556.89, $562.35 and $569.62 per share. Following these transactions, she held 40,513 shares of common stock directly, plus additional indirect holdings through her spouse and family trusts, including positions of 324,518 and 258,117 shares as of the filing.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share. On the same date, he sold 10,000 shares of common stock in multiple open-market trades at prices generally in the mid-$550s. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, he directly holds 18,876 shares of common stock and 112,500 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options and sold the resulting shares in a planned transaction. On 2026-04-06, she exercised options for 9,500 shares of common stock at an exercise price of $146.03 per share and then sold 9,500 shares in multiple open-market trades at prices ranging from $552.37 to $566.04.
The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Following these trades, she holds 40,513 shares directly, plus additional indirect holdings through her spouse and several family trusts.
United Therapeutics Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and acquired 9,500 shares on April 2, 2026. She then sold 9,500 shares of common stock the same day in a series of open‑market transactions at prices in the mid‑$500s per share, leaving her with 40,513 shares held directly. The filing also shows substantial additional indirect holdings through family trusts and a spouse. The exercise and sale were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of up to 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares in multiple open‑market transactions. The sales occurred at weighted average prices within ranges described in the filing, including from $551.68 to $571.72 per share. These transactions were carried out under a Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, Edgemond directly holds 18,876 shares of United Therapeutics Common Stock.
UNITED THERAPEUTICS Corp EVP & General Counsel Paul A. Mahon exercised stock options and sold the resulting shares in a pre-planned transaction. He exercised options for 8,300 shares of common stock at an exercise price of $146.03 per share and received 8,300 shares.
On the same date, he sold 8,300 shares of common stock in multiple open-market trades at weighted average prices generally around the mid-$560s per share, pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After these transactions, he directly owns 45,172 shares of UNITED THERAPEUTICS common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options for common stock at $146.03 per share and sold the resulting 9,500 shares in multiple open-market trades on April 1, 2026. The reported sale prices ranged from about the high $570s to high $590s per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares of common stock directly, plus indirect interests in shares held by her spouse and various family trusts. The plan permits exercise of up to 1,734,410 stock options that expire on March 17, 2027, and continues until those are exercised or December 31, 2026, whichever comes first.